Vischer advises Haya Therapeutics on completion of Seed Financing Round

Vischer acted as legal counsel for Haya Therapeutics, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), on the closing of its CHF 18 million seed round. The financing was led by Broadview Ventures, with participation from Apollo Health Ventures, BERNINA BioInvest, 4See Ventures, Schroder Adveq and Viva BioInnovator.

Vischer team is led by Christian Wyss (partner, corporate, pictured) with Lukas Züst (counsel, corporate) Pauline Pfirter (associate), Timothy Woodtli (associate, corporate), Francesca Pesenti (associate, corporate), Gian Geel (associate, employment), Adrian Briner (associate, tax).

Haya will use the funds from the financing to advance the discovery and development of innovative organ and cell-selective therapeutics that target lncRNAs to treat and potentially reverse fibrosis and other serious medical conditions related to aging.